Important: Formulation and dosage details
Formulation:
Tablets 5mg, 10mg
Dosage:
5mg daily, increased if necessary after 3 to 4 weeks to 10mg once daily.
test announcement
Patients’ response to drugs within this class is idiosyncratic. It may be necessary to try different drugs before a response occurs. Mirabegron is the first beta-3 adrenoceptor agonist to treat symptoms of overactive bladder and offers an alternative where anticholinergics are either not tolerated or are ineffective.
For guidance on the management of urinary incontinence in women refer to www.nice.org.uk.
For local continence care guidance and continence products see the North Highland Community Catheter and Appliances Formulary.
MHRA advice: Mirabegron (Betmiga) risk of severe hypertension and associated cerebrovascular and cardiac events (October 2015) (www.gov.uk).
Modified release tablets 25mg, 50mg
50mg once daily.
For dosing in patients with renal or hepatic impairment in the absence or presence of strong cytochrome P450 inhibitors such as itraconazole, ketoconazole, ritonavir, or clarithromycin, refer to SPC.
Tablets 2·5mg, 5mg
Initially 2·5 to 5mg 2 to 3 times daily increased if necessary to maximum 5mg 4 times daily
Modified release tablets 5mg, 10mg
Modified release: 5mg daily, adjusted according to response in 5mg steps at weekly intervals, maximum 20mg daily taken as a single dose.